Genosaber, focuses on development, manufacture, sale and technical support of tumor diagnostic products. The core technology, CTC (circulating-tumor-cell) based IVD (in vitro diagnostic) targeting on Lung cancer, is one of the most promising techniques in IVD. Genosaber has received CFDA approval in 2015, which is the first CTC product been approved. The product has been sold to top hospitals in Beijing, Shanghai and Guangzhou, including Beijing 301 Hospital, Beijing 307 Hospital, Shanghai Chest Hospital, Shanghai Pulmonary Hospital, Guangzhou Sun Yat-sen University Cancer Center, etc.
Products: CTC (circulating-tumor-cell) based IVD kit, targeting on Lung caner
Company Website: http://www.genosaber.com